Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Massive brain study seeks clues to schizophrenia

NCT ID NCT00001486

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 8 times

Summary

This completed study from the National Institute of Mental Health looked at nearly 5,000 people with schizophrenia or related disorders, along with their siblings. The goal was to find genes linked to the illness and see how they affect brain function. This research helps scientists better understand and potentially treat or prevent schizophrenia in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

4,914 people

The number who actually took part.

Started

Jul 1995

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Probands, healthy controls, siblings, parents

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION/EXCLUSION CRITERIA: Inclusion criteria for Siblings (probands and unaffected siblings): * Probands must have a DSM IV-R diagnosis of schizophrenia,schizoaffective disorder, psychosis N.O.S. or schizophreniform disorder. * Probands and Siblings must be between the ages of 18 and 55 * Probands and Siblings must be free of major medical illnesses, but may have controlled hypertension, thyroid disease, or diabetes. * Probands and Siblings must have the cognitive ability to consent for themselves. Those who are judged to have the cognitive ability to consent for themselves at the time of participation, but do not have the legal capacity to consent for themselves may participate if the legal guardian /Legal authorized representative (LAR) provides consent by signing the informed consent form. * Fluency in English is required. Exclusion Criteria for Siblings (probands and unaffected siblings): * Seizure disorder, mental retardation, organic brain damage or other neurological disease. * History of any (excepting nicotine-related) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence). * Cumulative lifetime history of any (excepting nicotine-related) DSM5-defined mild substance use disorder (or any DSM-IV-defined substance abuse), either in excess of 5 years total or not in remission for at least 6 months. * Head trauma with loss of consciousness over 5 minutes from all but genetic sampling. * Chemotherapy. * NIMH employees/staff and their immediate family members will be excluded from the study per NIMH policy Siblings who do not qualify for the 2-day or 1-day study, may participate in the limited phenotyping arm in which only a psychiatric interview and a blood draw for genetic analysis (SCID-DNA) will be performed, case control analysis or be included as part of a trio (one parent, one sibling, one patient) to study genetic transmission from parents to offsprings.. All parents are eligible for the study. Inclusion Criteria. Healthy Volunteers/Controls To be eligible for this research study, healthy volunteers must be: * Between the ages of 18 and 55 * Fluency in English is required Healthy Controls Exclusion Criteria: They will not be eligible if: * They have history of DSM IV-R psychiatric diagnosis or severe chronic medical illness at the time of the study. * They have a history of any (excepting nicotine-related) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence). * They have a cumulative lifetime history of any (excepting nicotine-related) DSM5-defined mild substance use disorder (or any DSM-IV-defined substance abuse), either in excess of 5 years total or not in remission for at least 6 months. * They may not be eligible for the 2-day or 1-day study if they have a first-degree relative with history of schizophrenia spectrum disorders. However, they may be included in the SCID\_DNA or case control analyses. * Healthy volunteers must be free of learning disabilities. * NIMH employees/staff and their immediate family members will be excluded from the study per NIMH policy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psychosis N.O.S. are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.